WDB Holdings Co., Ltd. (TYO:2475)

Inozyme Pharma Revenue

WDB Holdings had revenue of 12.97B JPY in the quarter ending June 30, 2025, with 0.61% growth. This brings the company's revenue in the last twelve months to 51.22B, up 3.00% year-over-year. In the fiscal year ending March 31, 2025, WDB Holdings had annual revenue of 51.14B with 3.73% growth.

• Revenue (ttm): 51.22B
• Revenue Growth: +3.00%
• P/S Ratio: 0.68
• Revenue / Employee: 9.39M
• Employees: 5,452
• Market Cap: 34.94B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	51.14B	1.84B	3.73%
Mar 31, 2024	49.30B	1.70B	3.56%
Mar 31, 2023	47.60B	727.00M	1.55%
Mar 31, 2022	46.88B	2.75B	6.23%
Mar 31, 2021	44.13B	1.02B	2.36%